The CRISPR field posted mixed news: CRISPR Therapeutics presented early clinical data showing a gene editing therapy halved cholesterol and triglycerides in an initial study, while Intellia disclosed a fatality tied to an acute liver injury in its MAGNITUDE Phase III program and is awaiting an FDA clinical‑hold letter. Companies and regulators are now scrutinizing safety signals alongside efficacy gains for in‑vivo genome editing. CRISPR Therapeutics’ cholesterol readout underscores in‑vivo editing’s potential for durable cardiometabolic benefit; Intellia’s adverse event prompted immediate review and public statements from investigators. The juxtaposition highlights the therapeutic promise and risk profile of in‑vivo CRISPR approaches and will likely shape regulatory dialogue, trial monitoring practices, and investor appraisal of genome‑editing programs.